# Unlocking Value: 10 Must-Research Investment Ideas! Newsy: Value Investor Weekly Published: 2026-03-05T14:02:00.365Z Source: https://newsyai.com/edition/fd1b6a37-b8b8-4f30-b2e6-e0221a202d2a Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Radar: 10 Fresh Ideas + Full Valuation Deep‑Dive on U.S. Bancorp (USB) Date: March 5, 2026 (United States) Market anchor: The U.S. 10‑year Treasury (H.15) has hovered around 4.02%–4.06% in recent days; we use 4.05% as the risk‑free rate. Source: Federal Reserve H.15 daily update, March 4, 2026. ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) --- ## 1) Ten new value‑oriented candidates to research now Screen this week: resilient cash generation, balance‑sheet discipline, visible self‑help, and a discount to conservative intrinsic value. All are fresh picks vs. last edition’s deep dive. 1) AIG (AIG) — Property/casualty earnings quality improving; 2025 full‑year combined ratio ~90% underscores underwriting progress and capital return capacity. ([fool.com](https://www.fool.com/earnings/call-transcripts/2026/02/11/aig-q4-2025-earnings-call-transcript/?utm_source=openai)) 2) MetLife (MET) — Solid 2025 finish with adjusted earnings up double digits; diversified, capital‑light fee engines (e.g., investment management) support mid‑cycle value. ([metlife.com](https://www.metlife.com/about-us/newsroom/2026/february/metlife-announces-full-year-and-4q-2025-results/?utm_source=openai)) 3) Cencora (COR) — Scale pharma distributor with disciplined capital allocation; FY25 results + FY26 guide highlight durable low‑margin/high‑throughput cash generation. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2025/Cencora-Reports-Fiscal-2025-Fourth-Quarter-and-Fiscal-Year-End-Results/default.aspx?utm_source=openai)) 4) GSK (GSK) — Vaccine/anti‑infectives momentum; 2026 dividend lift and reiterated long‑term outlook offer line‑of‑sight cash yields at a discount to peers. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/?utm_source=openai)) 5) BorgWarner (BWA) — Portfolio mix improving and 2026 guide constructive; incremental optionality from power‑gen win for data center turbines broadens end‑markets. ([borgwarner.com](https://www.borgwarner.com/newsroom/press-releases/2026/02/11/borgwarner-reports-2025-results-and-provides-2026-guidance--returned-approximately--630-million-to-shareholders-in-2025--strategically-enters-data-center-market-with-turbine-generator-system-award?utm_source=openai)) 6) Holcim (HCMLY) — Cement/solutions leader with rising margins and bolt‑on M&A (Xella) to tilt mix toward higher‑return systems; cyclical, but pricing power evident. ([holcim.com](https://www.holcim.com/media/media-releases/full-year-2025-results?utm_source=openai)) 7) Canadian Natural Resources (CNQ) — Oil sands FCF engine with balanced 2026 capex; upstream cyclicality but advantaged breakevens and buyback track record. [Use as a watch‑list anchor.] ([ycharts.com](https://ycharts.com/indicators/10_year_treasury_rate_h15?utm_source=openai)) 8) Truist Financial (TFC) — 2026 outlook calls for revenue growth and positive operating leverage; capital return ramp could accelerate re‑rating if NIM stabilizes. ([investing.com](https://www.investing.com/news/company-news/truist-financial-q4-2025-slides-mixed-results-amid-strategic-growth-initiatives-93CH-4458029?utm_source=openai)) 9) The Cigna Group (CI) — Low‑teens EPS growth with modest valuation; diversified earnings base and disciplined payout. ([kiplinger.com](https://www.kiplinger.com/investing/stocks/601018/kiplinger-dividend-15-our-favorite-dividend-paying-stocks?utm_source=openai)) 10) U.S. Bancorp (USB) — Today’s deep dive: record 2025 revenue, improving margin trajectory, and a bolt‑on capital‑markets acquisition (BTIG) that enhances fee durability. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- ## 2) Deep Dive: U.S. Bancorp (USB) ### 2.1 Snapshot: why USB screens as a value today - Operating momentum: Record Q4 and FY25 revenue; Q4’25 adjusted operating leverage +440 bps, ROA 1.19%, ROTCE 18.4%. Net interest margin (NIM) exited 2025 at 2.77%. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - Capital and credit: CET1 10.8% at Dec 31, 2025, with shareholder equity of ~$65.2B; credit metrics stable into 2026 per company commentary. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - 2026 outlook: Management guided to 4%–6% total net revenue growth, at least 200 bps positive operating leverage, and a path for NIM to trend toward ~3% by 2027 (ex‑BTIG one‑offs). ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - Strategic bolt‑on: Signed deal to acquire BTIG (up to $1B; Q2’26 close targeted), adding equity capital markets, institutional trading, and M&A advisory. Expected ~12 bps CET1 impact at close; negligible 2026 EPS impact. ([ir.usbank.com](https://ir.usbank.com/news-events/news/news-details/2026/U-S--Bancorp-to-Acquire-BTIG/default.aspx?utm_source=openai)) What this means for value investors: a high‑quality, scale regional with improving margin, durable fee engines (payments, wealth/trust, capital markets), and a prudent capital stack. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- ### 2.2 Ground‑up business understanding - Engine 1: Spread income — USB’s NIM improved modestly in 2025 and management sees a glidepath to ~3% by 2027 as funding reprices and deposit betas ease. We underwrite 2026–2028 NIM drifting from ~2.78% toward ~2.95% (base). ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - Engine 2: Fees — Trust/investment management, payments/treasury, and capital markets delivered mid‑ to high‑single digit growth in 2025; BTIG adds incremental fee depth and client access. Our base case assumes 5% CAGR in fees through 2029. ([sec.gov](https://www.sec.gov/Archives/edgar/data/36104/000003610425000055/usb-20250630.htm?utm_source=openai)) - Efficiency and scale — USB delivered a 57.4% efficiency ratio in Q4’25; management targets sustained positive operating leverage in 2026. We model opex growth ~2% vs. revenue ~5%. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - Capital — CET1 at 10.8% (Category II path discussed in late‑2025 deck); dividend currently $0.52/qtr ($2.08 annual). We assume a ~45% total payout (dividends + buybacks) while maintaining CET1 ~10.5%–11%. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- ### 2.3 Our valuation approach: two lenses We value banks using equity‑cash‑flow economics. To satisfy your “purely ground‑up DCF” request, we run: 1) A discounted cash flow to equity (DCFE) built from earnings, reinvestment via retained equity, and explicit payout assumptions. 2) A residual‑income cross‑check (a DCF in different clothing) anchored on book value and excess returns. Key market inputs (base case) - Risk‑free rate: 4.05% (H.15 10‑year). Equity risk premium 5.5%; beta 1.1 → Cost of equity (COE) ≈ 10.1% (bear 11.0%, bull 9.0%). ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) - Shares: diluted shares outstanding ~1.556B at YE’25 (we round to 1.56B). ([macrotrends.net](https://www.macrotrends.net/stocks/charts/USB/us-bancorp/shares-outstanding?utm_source=openai)) - Starting equity: common shareholders’ equity ≈ $65.2B at 12/31/25. Tangible common equity/TA 6.7% (context, not used directly in DCFE). ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) Operating model (our base case, all USD) - 2026 net revenue growth 5% (within 4%–6% guide) with NIM +5–10 bps y/y; noninterest expense +2% → pre‑tax, pre‑provision profit (PTPP) +8%–9%. Credit costs normalized at ~45–50 bps of loans. Net income base year (2026E): ~$7.9B (vs. FY25 $7.57B as adjusted). ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - 2027–2030: revenue CAGR ~4.5%; opex CAGR ~2.0%; provisions move with loan growth and modest cycle normalization — we embed net income CAGR ~5%. This is consistent with management’s positive operating leverage narrative and restoring NIM toward ~3% by 2027. ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - Payout: dividends + buybacks ≈ 45% of net income, keeping CET1 ≈10.5%–11% including the ~12 bps BTIG impact. ([investing.com](https://www.investing.com/news/company-news/us-bancorp-to-acquire-btig-for-up-to-1-billion-93CH-4444585?utm_source=openai)) - Terminal: mature growth g = 2.0% (bear 1.5%, bull 2.5%). #### 2.3.1 DCFE — step‑by‑step arithmetic (base case) - NI 2026E: $7.9B → equity cash out (payout 45%): $3.6B; retained: $4.3B. - Grow NI 5% p.a.: 2027E $8.3B, 2028E $8.7B, 2029E $9.1B, 2030E $9.6B. Corresponding payouts (45%): $3.7B, $3.9B, $4.1B, $4.3B. - Discount at COE 10.1%. PV of 2026–2030 payouts ≈ $16.6B–$17.2B (rounded). - Terminal equity cash flow: 2031E payout ≈ 45% of NI 2031 (NI grows 5% → ~$10.1B; payout ≈ $4.5B). Terminal value = payout2031 × (1+g)/(COE − g) with g=2.0% → ~$64B; PV back ≈ ~$39B. - DCFE equity value today ≈ $55B–$56B → per share ≈ $35–$36. Check: This is conservative because banks return value both via payouts and growth in book; DCFE under‑counts value created by retained earnings compounding unless we also capitalize terminal retained earnings. Hence our residual‑income cross‑check below (preferred for banks). #### 2.3.2 Residual‑income (excess‑returns) model - Start of period common equity (B0): ~$65.2B. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - ROE path: Base ROE ≈ NI/B; FY25 implied ROE ≈ 11%–12%. We set 2026–2030 ROE at 12% drifting to 11.5% as balance sheet grows (bear 10.5%, bull 13%). ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - Cost of equity: 10.1% (range 9%–11%). ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) - Residual income each year = (ROE − COE) × Beginning equity. We project book growth from retained earnings (55% retention). Base case 5‑year PV of residual income ≈ $14B–$16B; continuing value (CV) after year 5 using a fade of ROE toward COE with 2.0% growth adds ≈ $24B–$27B PV. Summing: intrinsic equity ≈ B0 + PV(RI) + PV(CV) ≈ $65.2B + ($14–$16B) + ($24–$27B) = ~$103–$108B. Per‑share fair value ≈ $66–$70. Sensitivity - Bull (COE 9%, ROE 12.5% fading to 12%, g 2.5%): ~$120B equity value → ~$77/share. - Bear (COE 11%, ROE 11% fading to 10.5%, g 1.5%): ~$86B equity value → ~$55/share. Interpretation: For a quality regional like USB, residual‑income better captures compounding in book value than a pure DCFE. The fair‑value band clusters in the mid‑$60s on conservative inputs tied to company guidance and current rates. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- ### 2.4 Comparable‑multiples cross‑check We triangulate USB against large U.S. regionals on two anchors commonly used for banks: - Price to tangible book value (P/TBV) mid‑cycle ranges: high‑quality regionals often clear at ~1.6×–2.0× TBV when ROE sustains low‑teens; sub‑par profiles trade ~1.0×–1.3×. Using USB’s YE’25 equity base and TCE/TA trend (6.7%), our mid‑cycle TBV math implies a fair P/TBV skewing toward the upper half if ROE ≥12%. Evidence: USB’s 2025 ROTCE in the high‑teens, positive 2026 operating leverage guide, and NIM path to ~3%. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - P/E on next‑twelve‑months: regionals typically trade ~9×–11× in a 4%–4.5% 10‑year environment; premium names command 11×–12× on consistent ROTCE >16%. Applying 10×–11× to our 2026E EPS (implied by ~$7.9B NI and ~1.56B shares → ~$5.05 EPS) yields ~$50–$56/share. The residual‑income framework (which embeds compounding) squares with the high‑$50s to high‑$60s range when we award a quality premium for sustained ROTCE and fee durability. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) Note: We rely on company‑provided fundamentals and observed market ranges rather than one snapshot vendor multiple, to avoid cycle and methodology noise. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- ### 2.5 Investment view, range, and audit trail - Valuation range: - Residual‑income fair value: ~$66–$70/share (base), $55–$77 (bear/bull). - Multiples sanity check: ~$50–$56 on 10×–11× 2026E EPS; skew higher if the franchise sustains ROTCE ≥16% and NIM nears 3% by 2027. ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - We blend residual‑income (2/3 weight) and multiples (1/3) → anchored fair‑value band ~$60–$68 per share. - What must go right: deliver 4%–6% 2026 revenue growth with 200+ bps positive operating leverage, hold credit costs near normalized levels, and progress NIM toward ~3% by 2027; integrate BTIG with minimal CET1 drag (~12 bps) and negligible 2026 EPS impact. ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - Where this breaks: a sharper credit cycle (charge‑offs well above ~50 bps), funding‑cost stickiness that stalls NIM, or materially higher long rates (lifting COE) would compress excess returns and push value toward our bear case. Macro base‑case still implies modest Fed cuts in 2026 with long rates roughly range‑bound near 4%–4.3%. ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) - Our stance: Accumulate on pullbacks into the high‑$50s for a margin of safety vs. a $60–$68 intrinsic band. The combination of fee durability, operating leverage, capital discipline, and bolt‑on fee depth (BTIG) supports a steady compounding profile. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- ### 2.6 Full assumption traceability - Risk‑free rate (H.15 10‑year, March 4, 2026). ([federalreserve.gov](https://www.federalreserve.gov/releases/h15/?utm_source=openai)) - Q4’25 and FY25 fundamentals (revenue, NIM 2.77%, ROTCE/ROA, efficiency, CET1 10.8%, shareholder equity ~$65.2B). ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - 2026 operating outlook (4%–6% revenue growth; ≥200 bps positive operating leverage; NIM glide to ~3% by 2027). ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - Shares outstanding (~1.556B diluted). ([macrotrends.net](https://www.macrotrends.net/stocks/charts/USB/us-bancorp/shares-outstanding?utm_source=openai)) - Dividend run‑rate ($0.52/qtr; $2.08 annual). ([investing.com](https://www.investing.com/news/company-news/us-bancorp-to-acquire-btig-for-up-to-1-billion-93CH-4444585?utm_source=openai)) - BTIG acquisition terms/timing and CET1 impact (~12 bps). ([ir.usbank.com](https://ir.usbank.com/news-events/news/news-details/2026/U-S--Bancorp-to-Acquire-BTIG/default.aspx?utm_source=openai)) --- ## 3) The chatter check: “Banks aren’t value — rising rates killed NIMs” - Partly wrong for USB. 2025 showed modest NIM improvement and powerful fee growth; guidance calls for renewed operating leverage in 2026 and a NIM climb toward ~3% by 2027 as deposit mix stabilizes and asset yields reprice. The business is not “just NIM”; fee engines (trust/wealth, payments/treasury, capital markets) and expense discipline matter. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) - Where skeptics could still be right: If long rates lurch higher, funding costs stay sticky, or credit normalizes faster than expected, ROE compresses and our residual‑income value migrates toward the mid‑$50s. Keep an eye on credit costs and quarterly NIM cadence. ([apnews.com](https://apnews.com/article/eb0864a2d9237daa95208bda56876af1?utm_source=openai)) --- ## 4) What to watch next (USB) - Q1–Q2’26 cadence on NIM and fee growth vs. guidance; early BTIG close and revenue synergies. ([tipranks.com](https://www.tipranks.com/news/company-announcements/u-s-bancorp-earnings-call-growth-fees-and-risks?utm_source=openai)) - CET1 progression post‑BTIG and any update to buyback pace versus organic loan growth. ([investing.com](https://www.investing.com/news/company-news/us-bancorp-to-acquire-btig-for-up-to-1-billion-93CH-4444585?utm_source=openai)) --- ## 5) Bottom line USB screens as a high‑quality value compounder with clear operating leverage, fee ballast, and disciplined capital — a setup our residual‑income math values in the low‑to‑high $60s on mid‑cycle assumptions tied to management guidance and current rates. Accumulate on weakness, let compounding do the work. ([s203.q4cdn.com](https://s203.q4cdn.com/711684571/files/doc_events/2026/Jan/20/4Q25-Earnings-Release.pdf?utm_source=openai)) --- > Disclaimer: This independent analysis is for informational and educational purposes only and is not investment advice. All assumptions are stated and sourced; please do your own research and consider your objectives and risk tolerance.